% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Frost:307521,
author = {N. Frost and M. Joosten and J. Franzen and M. Wiesweg and
A. Rasokat and J. Kulhavy and J. Kollmeier and N. Reinmuth
and C. Grohé and J. Roeper and A. Rittmeyer and S. Heinzen
and M. Wermke and C. Wesseler and P. Christopoulos and D.
Kauffmann-Guerrero and A. Althoff and A. Bleckmann and M.
Collienne$^*$ and E. Berezucki and T. Overbeck and C.
Kropf-Sanchen$^*$ and F. Griesinger and M. Sebastian and M.
Schuler and S. Braun and C. Wenzel and C. Furth and J. Wolf
and P. Bischoff$^*$ and M. Reck},
collaboration = {N. N. G. M. L. C. Germany},
othercontributors = {N. Frost$^*$ and M. Joosten and J. Franzen and M. Wiesweg
and A. Rasokat and J. Kulhavy and J. Kollmeier and N.
Reinmuth and C. Grohé and J. Röper and A. Rittmeyer and S.
Heinzen and M. Wermke and C. Wesseler and P. Christopoulos
and D. Kauffmann-Guerrero and A. Althoff and A. Bleckmann
and M. Collienne$^*$ and E. Berezucki and T. Overbeck and C.
Kropf-Sanchen$^*$ and F. Griesinger and M. Sebastian and M.
Schuler and S. Braun and C. Wenzel and C. Furth and J. Wolf
and P. Bischoff$^*$ and M. Reck and M. Hilbrandt and D.
Horst and H.-D. Hummel and M. Kemper and A. Kron and S.
Loges$^*$ and H. Lüders and S. Ochsenreither$^*$ and M.
Raspe and F. Saalfeld and C. Schulz and S. Terrahe and M.
Thomas and P. J. Wild},
title = {{PET}/{CT}-{G}uided {M}anagement of {I}mmune {C}heckpoint
{B}lockade and {P}ost-{T}reatment {M}ulti-{M}odal
{P}rofiling in {L}ong-{T}erm {R}esponders with {M}etastatic
{L}ung {C}ancer in the {N}ational {N}etwork {G}enomic
{M}edicine {L}ung {C}ancer {G}ermany (n{NGM}).},
journal = {Annals of oncology},
volume = {nn},
issn = {0923-7534},
address = {Amsterdam [u.a.]},
publisher = {Elsevier},
reportid = {DKFZ-2026-00026},
pages = {nn},
year = {2025},
note = {epub},
abstract = {The optimal duration of immune checkpoint blockade (ICB) in
lung cancer remains undefined. Indefinite treatment in
long-term responders increases healthcare burden, exposes
patients to avoidable toxicities, and is not supported by
any clinical and biological rationale or translational data.
Prospective strategies to determine the optimal duration of
immunotherapy in lung cancer are urgently needed.In this
retrospective cohort study, 455 patients from 21 nNGM
centers with ≥2 years of disease control on first-line
ICB-based therapy were grouped into PET/CT-guided
discontinuation (cohort A, n=126) or continued ICB without
PET/CT (cohort B, n=329), and assessed for overall survival
(OS). Matched pre- and post-ICB tumor samples from cohort A
patients with persistent or progressive disease were
analyzed by comprehensive genomic profiling, histological
TIL quantification, and spatial transcriptomics to explore
mechanisms of late resistance.After a median follow-up of 55
months, cohort A showed significantly longer OS (median not
reached vs. 82 months; HR 0.35 [0.18-0.67], p = 0.002),
despite substantially shorter treatment duration (27 vs. 45
months; p < 0.001). Discontinuation was either PET-driven
(A) or resulted from immune-related toxicity, progression,
or patients' choice (B). Systematic re-biopsies in cohort A
revealed a high incidence of second primary lung cancers
(SPLC, $28\%).$ All progression events were managed
exclusively with local (ablative) treatments in $53\%$ (A)
vs. $17\%$ (B). Post-treatment tumors exhibited features of
acquired resistance, whereas SPLC displayed characteristics
of primary resistance, including low PD-L1 expression, low
TMB, and immunologically cold tumor microenvironments.A
structured discontinuation strategy appears to provide a
safe approach for long-term ICB responders, enabling earlier
detection of resistance before generalized progression. A
confirmatory prospective non-inferiority randomized trial
within the nNGM is underway.},
keywords = {Lung cancer (Other) / discontinuation (Other) / immune
checkpoint blockade (Other) / long-term response (Other) /
resistance mechanisms (Other) / second primary lung cancer
(Other)},
cin = {A420 / BE01},
ddc = {610},
cid = {I:(DE-He78)A420-20160331 / I:(DE-He78)BE01-20160331},
pnm = {311 - Zellbiologie und Tumorbiologie (POF4-311)},
pid = {G:(DE-HGF)POF4-311},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:41478526},
doi = {10.1016/j.annonc.2025.12.011},
url = {https://inrepo02.dkfz.de/record/307521},
}